PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Войти

Зарегистрироваться
Забыли пароль?

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20170730 151435
20170801 201454
20170804 165409
DJI 0002
IMG-20170807-WA0002
20170730 123751
  • Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 15, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Q1 Stability Testing of Drug Substances and Drug Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-23 By FDA
  • Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Date of authorisation: 20/02/2014, Revision: 24, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Grepid, clopidogrel, Date of authorisation: 27/07/2009, Revision: 29, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Nustendi, bempedoic acid,ezetimibe, Date of authorisation: 27/03/2020, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • Human medicines European public assessment report (EPAR): Nilemdo, bempedoic acid, Date of authorisation: 01/04/2020, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-23
  • October 10, 2024: Meeting of the Cardiovascular and Renal Drugs Advisory Committee - 10/10/2024
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
  • User Fee Lists
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-21 By FDA
  • Counterfeit Medicine
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • PREA Non-Compliance Letters
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
  • Internet Pharmacy Warning Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-20 By FDA
  • DG Gel Card 125445, 125449, 125450 - 125457
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-20 By FDA
  • Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine,tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,raxtozinameran, Date of authorisation: 21/12/2020, Revision: 54, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-20
Предыдущие записи
Тема: Scaffold от Danny Cooper.